Hillstream Biopharma Stock Fundamentals
Hillstream Biopharma fundamentals help investors to digest information that contributes to Hillstream Biopharma's financial success or failures. It also enables traders to predict the movement of Hillstream Stock. The fundamental analysis module provides a way to measure Hillstream Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hillstream Biopharma stock.
Hillstream |
Hillstream Biopharma Company Current Valuation Analysis
Hillstream Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hillstream Biopharma Current Valuation | 496.66 K |
Most of Hillstream Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hillstream Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Hillstream Biopharma has a Current Valuation of 496.66 K. This is 100.0% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Hillstream Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hillstream Biopharma's current stock value. Our valuation model uses many indicators to compare Hillstream Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hillstream Biopharma competition to find correlations between indicators driving Hillstream Biopharma's intrinsic value. More Info.Hillstream Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Hillstream Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Hillstream Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hillstream Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hillstream Biopharma could also be used in its relative valuation, which is a method of valuing Hillstream Biopharma by comparing valuation metrics of similar companies.Hillstream Biopharma is currently under evaluation in current valuation category among its peers.
Hillstream Fundamentals
| Return On Equity | -1.47 | |||
| Return On Asset | -0.78 | |||
| Current Valuation | 496.66 K | |||
| Shares Outstanding | 17.53 M | |||
| Shares Owned By Insiders | 38.90 % | |||
| Shares Owned By Institutions | 0.80 % | |||
| Number Of Shares Shorted | 52.74 K | |||
| Price To Book | 0.88 X | |||
| EBITDA | (6.88 M) | |||
| Net Income | (8.47 M) | |||
| Cash And Equivalents | 9.48 M | |||
| Cash Per Share | 0.82 X | |||
| Total Debt | 772.9 K | |||
| Current Ratio | 13.13 X | |||
| Book Value Per Share | 0.18 X | |||
| Cash Flow From Operations | (6.56 M) | |||
| Short Ratio | 0.20 X | |||
| Earnings Per Share | (0.76) X | |||
| Target Price | 4.0 | |||
| Market Capitalization | 4.23 M | |||
| Total Asset | 6.69 M | |||
| Retained Earnings | (15.38 M) | |||
| Working Capital | 5.54 M | |||
| Z Score | -2.34 | |||
| Net Asset | 6.69 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Hillstream Stock
If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |